High ORRs Seen with Tagraxofusp-erzs in BPDCN
- PMID: 31126990
- DOI: 10.1158/2159-8290.CD-NB2019-061
High ORRs Seen with Tagraxofusp-erzs in BPDCN
Abstract
Tagraxofusp-erzs is an effective therapy for blastic plasmacytoid dendritic-cell neoplasm, according to recently published results from a multistage trial that led to the drug's 2018 approval. In the trial, the drug elicited high overall response rates, and many patients went on to receive a stem-cell transplant. However, it also caused some serious side effects.
©2019 American Association for Cancer Research.
Comment on
-
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105. N Engl J Med. 2019. PMID: 31018069 Clinical Trial.